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Abstract — Electroporation refers to exposure of cells to external electric 
field thatresults in transiently or permanently increased permeability of cell 
membranes. Cancer treatment, where local application of electroporation 
to tumor nodules is combined with chemotherapeutic drugs bleomycin 
or cisplatin is called electrochemotherapy. The antitumor effectiveness of 
electrochemotherapy is primarily based on direct killing of tumor cells due to 
the increased chemotherapeutic drug uptake, but other mechanisms, such 
as vascular disrupting action was also demonstrated. Our group is involved 
in elucidating the underlying mechanism of vascular disrupting action by 
studying the changes in cytoskeletal proteins after electrochemotherapy in 
endothelial cells by immunocytochemistry. In addition, metastatic potential 
and global changes in gene expression of melanoma cells that survived 
electrochemotherapy were also studied, demonstrating that metastatic 
potential of cells is not changed and that a very low percentage of genes are 
down or up regulated after electrochemotherapy, which further supports 
its safe use in the clinical setting. Another application of electroporation is 
delivery of plasmid DNA into the cells for gene therapy. Our group is involved in 
preparation of plasmid DNA with tissue specific promoters and without genes 
for antibiotic resistance, thus enabling safe use of gene therapy in line with USA 
Food and Drug Administration (FDA) and European medicines Agency (EMA) 
recommendations.
Index Terms — electrochemotherapy, electrogene therapy,electroporation, 
preparation of plasmids without genes for antibiotic resistance.
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1 INTRODUCTION
Due to the physical nature of the method, all types of living cells (prokaryotic and eukaryotic) can be efficiently electroporated. Currently electroporation is used 
in food and biomass processing and as a cancer treatment. In food processing, the 
aim is to kill the microorganisms, while preserving the color, taste and the level of 
antioxidant in the processed food. Electroporation was successfully used for extraction 
of intracellular components from plant and has shown a potential in pretreatment 
of sludge and other substrates leading to increase in biogas production. Other 
applications, such as water treatment, extraction of oil from algae, sugar extraction 
from sugar beet are also being investigating. In cancer treatment, electroporation 
is currently used in combination with the chemotherapeutic drugs bleomycin and 
cisplatin for treatment of cutaneous and subcutaneous metastases of various 
histological types of tumors. Electroporation can also be used for introduction of 
genetic material - plasmid DNA - into the cells and therefore used for DNA vaccination 
and gene therapy of various diseases.
2 ELECTROChEMOThERAPy – EFFECTS ON ENDOThELIAL CELLS
Electrochemotherapy consists of chemotherapy followed by local application of electric pulses to the tumor to increase drug delivery into cells. Drug uptake can 
be increased by electroporation only for those drugs whose transport through the 
plasma membrane is normally impeded. Among many drugs which have been tested 
so far, only bleomycin and cisplatin have transitioned from preclinical testing to 
clinical trials. In vitro studies demonstrated a several-fold increase in their cytotoxicity 
after electroporation of cells. In vivo, electroporation of tumors after local or systemic 
administration of either of the drugs, i.e. electrochemotherapy, proved to be an 
effective antitumor treatment. Several clinical studies were performed demonstrating 
that electrochemotherapy is effective in local tumor control of cutaneous and 
subcutaneous tumor nodules of different histology. So far, predominantly melanoma 
skin metastases have been treated, with ~70% long-lasting complete responses of 
the treated nodules [1]. Electrochemotherapy is also used in veterinary oncology, 
where it is used also for treatment of primary tumors and with similar results as in 
human medicine [2].
Besides membrane electroporation, which facilitates drug transport and its 
accumulation in the cell, other mechanisms that are involved in antitumor 
effectiveness of electrochemotherapy, have been described, potentiation of immune 
response, blood-flow modifying effect and vascular disrupting action. The application 
of electric pulses to tissues induces a transient but reversible reduction in blood 
flow. In vitro studies have shown that application of electric pulses to a monolayer 
of endothelial cells results in a profound disruption of microfilament and microtubule 
cytoskeletal networks, loss of contractility, and loss of cadherin-formed cell-to-cell 
junctions in the vascular endothelial lining immediately after electroporation, which 
recovered within 60 minutes after electroporation, without any significant loss of cell 
viability. The cytoskeletal effects of electroporation were paralleled by a rapid increase 
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in endothelial monolayer permeability, giving an indication of putative mechanisms 
responsible for the observed increase in permeability and cessation of blood flow in 
vivo[3]. When electroporation is combined with chemotherapeutic drugs the effects 
on vasculature are even more pronounced and resulted in electrochemotherapy with 
bleomycin in complete abrogation of blood flow in vivo. Currently, we are exploring 
the underlying mechanisms of this effect at the cellular level, by studying the effects 
of electrochemotherapy on adherent microvascular endothelial cells. We found that 
nuclear morphology changes as well as changes in microtubules and actin filaments 
network are more profound and long lasting after electrochemotherapy with 
bleomycin compared to changes induced by electroporation or bleomycin alone (Fig. 
1). In addition, endothelial monolayer intactness was severely compromised after 
electrochemotherapy.
Fig. 1.Monolayers of Human Microvascular Endothelial Cells (HMEC-1) are differently affected by elec-
troporation (EP) and electrochemotherapy (ECT).Monolayers stained for F-actin with FITC conjugated phal-
loidin. Note the honeycomblike appearance at 0 hrs for both 300V EP and ECT. Recovery is present at 24 
hrs post-treatment, while in the presence of 300 nM bleomycin (ECT) cells start to die.
3 ELECTROChEMOThERAPy – EFFECTS ON METASTATIC POTENTIAL 
 OF MELANOMA CELLS
Another topic of our research in the field of electrochemotherapy was to address the clinical relevant question i.e. if metastatic potential and global 
gene expression of melanoma cells that survive electrochemotherapy is changed. 
Namely, it is known that metastatic progression is a multi-step process that requires 
acquisition of many specific cell properties, each fulfilling a unique function in the 
metastatic cascade for successful establishment of metastases. Alterations in tumor 
cells and their microenvironment induced by therapy can play an important role in 
metastasis induction. We studied on viable cells 48 hours after electrochemotherapy 
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their ability to migrate and invade through Matrigel coated porous membrane. In 
addition, microarray analysis was used to detect changes in gene expression after 
electrochemotherapy. Cell migration and invasion were not changed in melanoma 
cells surviving electrochemotherapy. In addition, only a low number of tumorigenesis 
related genes was differentially expressed after electrochemotherapy (Fig. 2), 
demonstrating that the metastatic potential of melanoma cells was not affected by 
electrochemotherapy and confirming its safety in the clinics [4], [5].
Fig. 2.Differentially expressed tumorigenesis related genes after electrochemotherapy. From 0,5% to 1,3% 
of all evaluated genes were differentially expressed after exposure to electroporation (EP), cisplatin (CDDP), 
bleomycin (BLM) or electrochemotherapy (ECT) with CDDP or BLM. Bars represent percentage of down 
regulated or up regulated genes of the total number of tested genes.
4 ELECTROGENE ThERAPy – PREPARATION OF PLASMID DNA WIThOUT   
 ANTIBIOTIC RESISTANCE GENE
Another application of electroporation is delivery of genetic material i.e. plasmid DNA into the cells. Due to the concerns connected to viral vectors, non-viral 
approaches for transfection are becoming very attractive [6]. One of the goals of 
researchers dealing with gene therapy or DNA vaccination is to develop safe and 
efficient systems for gene transfer into the target cells. Namely, this topic is still 
one the major hurdles in the progress of different approaches in gene therapy and is 
crucial factor for success of the therapy. Other factors that should be considered for 
development of gene therapy are the choice of appropriate therapeutic gene, regulation 
of its expression and administration route. Our group at the College of Health Care 
Izola in collaboration with Institute of Oncology Ljubljana, National Institute of Biology 
and University of Ljubljana Biotechnical faculty is planning to address two of these 
factors for the use in cancer gene therapy: safety of plasmid DNA by preparation of 
plasmid DNA without marker for antibiotic resistance and regulation of therapeutic 
gene expression by linking the therapeutic gene to cellular promoters to achieve 
either stress induced (p21 and radiation) or physiological regulation (tissues specific 
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promoters for endothelial and muscle cells and fibroblasts) of expression. We are 
planning to prepare plasmids encoding reporter or therapeutic genes under the 
control of tissue specific or inducible promoters using standard molecular biology 
techniques and plasmids without gene for antibiotic resistance according to the 
instructions of the producer of ORT® plasmid. The results of this on-going project, if 
successful, may have impact on design and execution of gene therapy trials.
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